NCT01294579 - Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2011

Primary Completion Date

December 20, 2016

Study Completion Date

December 20, 2016

Conditions

Lymphoma, Non-Hodgkin

Interventions

BIOLOGICAL

Ofatumumab

"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"

DRUG

Bendamustine

90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)

Trial Locations (22)

27518

Novartis Investigative Site, Cary

27607

Novartis Investigative Site, Raleigh

28204

Novartis Investigative Site, Charlotte

29414

Novartis Investigative Site, Charleston

29601

Novartis Investigative Site, Greenville

32073

Novartis Investigative Site, Orange Park

45429

Novartis Investigative Site, Kettering

75090

Novartis Investigative Site, Sherman

75702

Novartis Investigative Site, Tyler

76712

Novartis Investigative Site, Waco

78229

Novartis Investigative Site, San Antonio

80045

Novartis Investigative Site, Aurora

85224

Novartis Investigative Site, Chandler

89169

Novartis Investigative Site, Las Vegas

91505

Novartis Investigative Site, Burbank

93030

Novartis Investigative Site, Oxnard

93720

Novartis Investigative Site, Fresno

97401

Novartis Investigative Site, Eugene

98684

Novartis Investigative Site, Vancouver

98902

Novartis Investigative Site, Yakima

01805

Novartis Investigative Site, Burlington

68198-9200

Novartis Investigative Site, Omaha